Sulfolobus islandicus, an archaeal model organism, offers unique advantages for metabolic engineering and synthetic biology ...

The biotech is developing drugs that target the biology of aging to treat obesity, cardiovascular disease, and more ...

Soley Therapeutics has secured $200 million in series C funds, which the artificial-intelligence-enabled biotech plans to use ...

By ending its agreement with ImmuneOnco, Instil is also handing back the other asset from the licensing deal: IMM27M, a next-gen anti-CTLA-4 antibody that ImmuneOnco had taken into phase 1 trials as a ...

Nanoparticle technology offers significant market opportunities in pharmaceuticals and biomedicine, enhancing drug delivery, solubility, and targeted therapy. This field supports advancements in ...

It’s the latest move in the race by drug companies to corner more of the highly lucrative obesity drug market.

After a prolonged funding chill, investors say 2026 is shaping up for continued dealmaking and diversified bets beyond ...

Variant Bio, a private biotech firm, said on Tuesday it has launched a platform that uses artificial intelligence on genetic ...

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter: Alumis: Top-line ...

Only a handful of the top pharmas have signed Most Favored Nation drug pricing deals with the White House, while smaller ...